All In Biotech

Drug Trial Radar · NCT02463032

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Aug 2015

Primary completion

Mar 2019

Study completion Mar 2019

Sponsor

Lead sponsor
GTxIndustry
Sponsor type
Industry
First posted
Jun 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.

Conditions

  • ER+ and AR+ Breast Cancer

Interventions

  • GTx-024Drug

    To determine whether either or both doses result in an acceptable clinical benefit rate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ SubjectsTime frame: 24 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • The West Clinic, PC

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.